Edition:
United Kingdom

People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

9.27USD
4:50pm BST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$9.27
Open
$9.27
Day's High
$9.39
Day's Low
$9.19
Volume
10,438
Avg. Vol
136,229
52-wk High
$19.67
52-wk Low
$8.07

Scarlett, John 

Dr. John A. Scarlett, M.D. serves as Independent Director of the Company. Dr. Scarlett has served as a member of our Board since June 2016. Dr. Scarlett currently serves as chief executive officer, president and a member of the board of directors of Geron Corporation, a public company. Since February 2015, Dr. Scarlett has also served as a member of the board of directors of Chiasma, Inc., a public company. Prior to joining Geron in September 2011, Dr. Scarlett served as president, chief executive officer and a member of the board of directors of Proteolix, Inc., from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., in November 2009. From February 2002 until its acquisition by Ipsen, S.A., in October 2008, Dr. Scarlett served as founder, chief executive officer and a member of the board of directors of Tercica, Inc., and also as its president from February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett served as president and chief executive officer of Sensus Drug Development Corporation. In 1995, he cofounded Covance Biotechnology Services, Inc., and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as senior vice president of medical and scientific affairs at Novo Nordisk Pharmaceuticals, Inc. Dr. Scarlett holds a B.A. in chemistry from Earlham College and an M.D. from the University of Chicago, Pritzker School of Medicine. We believe Dr. Scarlett is qualified to serve on our Board based on his significant industry experience, medical background and extensive management experience in the life sciences sector.

Basic Compensation

Total Annual Compensation, USD 53,750
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 201,036
Fiscal Year Total, USD 254,786

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Sean McCarthy

5,482,230

Lloyd Rowland

1,793,490

Nick Galli

--

W. Michael Kavanaugh

1,774,610

Matthew Young

220,418

Elaine Jones

--
As Of  31 Dec 2018